当前位置: 首页 >> 检索结果
141. Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension.
作者: Marius M Hoeper.;Ralf Ewert.;Pavel Jansa.;Yuriy Sirenko.;Andris Skride.;Cecile Balagtas.;Sarah Hackley.;Susanne Vogt.;Paula Abreu.;Scott Haughie.;Tarek Hassan.;Ronald J Oudiz.
来源: Circulation. 2024年149卷25期1949-1959页
Sildenafil, approved for pulmonary arterial hypertension (PAH), has a recommended adult dose of 20 mg TID, with a previously approved 5-mg TID dose by the US Food and Drug Administration. Safety concerns arose because of common off-label use of higher doses, particularly after pediatric data linked higher doses to increased mortality. To assess this, the Food and Drug Administration mandated a study evaluating the effects of various sildenafil doses on mortality in adults with PAH.
142. Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial).
作者: Heerajnarain Bulluck.;Jun Hua Chong.;Jennifer Bryant.;Annitha Annathurai.;Ping Chai.;Mervyn Chan.;Ashish Chawla.;Chee Yang Chin.;Yiu-Cho Chung.;Fei Gao.;Hee Hwa Ho.;Andrew Fu Wah Ho.;John Hoe.;Syed Saqib Imran.;Chi-Hang Lee.;Benji Lim.;Soo Teik Lim.;Swee Han Lim.;Boon Wah Liew.;Patrick Lim Zhan Yun.;Marcus Eng Hock Ong.;Valeria Paradies.;Xuan Ming Pung.;Julian Cheong Kiat Tay.;Lynette Teo.;Boon Ping Ting.;Aaron Wong.;Evelyn Wong.;Timothy Watson.;Mark Y Chan.;Yeo Khung Keong.;Jack W C Tan.;Derek J Hausenloy.; .
来源: Circulation. 2024年150卷2期91-101页
The administration of intravenous cangrelor at reperfusion achieves faster onset of platelet P2Y12 inhibition than oral ticagrelor and has been shown to reduce myocardial infarction (MI) size in the preclinical setting. We hypothesized that the administration of cangrelor at reperfusion will reduce MI size and prevent microvascular obstruction in patients with ST-segment-elevation MI undergoing primary percutaneous coronary intervention.
143. Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study.
作者: Aditya S Bharadwaj.;Arsalan Abu-Much.;Aneel S Maini.;Zhipeng Zhou.;Yanru Li.;Wayne B Batchelor.;Cindy L Grines.;Suzanne J Baron.;Björn Redfors.;Alexandra J Lansky.;Mir B Basir.;William W O'Neill.
来源: Circ Cardiovasc Interv. 2024年17卷7期e013503页
Prior studies have found that patients with chronic kidney disease (CKD) have worse outcomes following percutaneous coronary intervention (PCI). There are no data about patients with advanced CKD undergoing Impella-supported high-risk PCI. We, therefore, aimed to evaluate angiographic characteristics and clinical outcomes in patients with CKD who received Impella-supported high-risk PCI as part of the catheter-based ventricular assist device PROTECT III study (A Prospective, Multi-Center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus Intra Aortic Balloon Pump [IABP] in Patients Undergoing Non Emergent High Risk PCI).
144. Cross-Seal IDE Trial: Prospective, Multicenter, Single-Arm Study of the Cross-Seal Suture-Mediated Vascular Closure Device System.
作者: Prakash Krishnan.;Serdar Farhan.;Frank Zidar.;Zvonimir Krajcer.;Christopher Metzger.;Samir Kapadia.;Erin Moore.;Tamim Nazif.;Ty Garland.;Ming Zhang.;Sahil Khera.;Mel Sharafuddin.;Virendra I Patel.;John Michael Bacharach.;Paul Coady.;Marc L Schermerhorn.;Murray L Shames.;Saum Rahimi.;Jean M Panneton.;Craig Elkins.;Mazin Foteh.
来源: Circ Cardiovasc Interv. 2024年17卷6期e013842页
An increasing number of interventional procedures require large-sheath technology (>12F) with a favorable outcome with endovascular rather than open surgical access. However, vascular complications are a limitation for the management of these patients. This trial aimed to determine the effectiveness and safety of the Cross-Seal suture-mediated vascular closure device in obtaining hemostasis at the target limb access site following interventional procedures using 8F to 18F procedural sheaths.
145. Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial.
作者: Kenta Nakamura.;Timothy D Henry.;Jay H Traverse.;David A Latter.;Nahush A Mokadam.;Geoffrey A Answini.;Adam R Williams.;Benjamin C Sun.;Christopher R Burke.;Faisal G Bakaeen.;Marcelo F DiCarli.;Bernard R Chaitman.;Mark W Peterson.;Dawn G Byrnes.;E Magnus Ohman.;Carl J Pepine.;Ronald G Crystal.;Todd K Rosengart.;Elaine Kowalewski.;Gary G Koch.;Howard C Dittrich.;Thomas J Povsic.; .
来源: Circ Cardiovasc Interv. 2024年17卷5期e014054页
XC001 is a novel adenoviral-5 vector designed to express multiple isoforms of VEGF (vascular endothelial growth factor) and more safely and potently induce angiogenesis. The EXACT trial (Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment) assessed the safety and preliminary efficacy of XC001 in patients with no option refractory angina.
146. Intermittent Fasting After ST-Segment-Elevation Myocardial Infarction Improves Left Ventricular Function: The Randomized Controlled INTERFAST-MI Trial.
作者: Jochen Dutzmann.;Zoe Kefalianakis.;Florian Kahles.;Jan-Marcus Daniel.;Hubert Gufler.;Walter Alexander Wohlgemuth.;Kai Knöpp.;Daniel G Sedding.
来源: Circ Heart Fail. 2024年17卷5期e010936页
Intermittent fasting has shown positive effects on numerous cardiovascular risk factors. The INTERFAST-MI trial (Intermittent Fasting in Myocardial Infarction) has been designed to study the effects of intermittent fasting on cardiac function after STEM (ST-segment-elevation myocardial infarction) and the feasibility of future multicenter trials.
147. Active Arrhythmia Pattern: A Novel Predictor of ICD Shocks-A Subanalysis From the PARTITA Study.
作者: Andrea Radinovic.;Daniele Giacopelli.;Caterina Bisceglia.;Gabriele Paglino.;Alessio Gargaro.;Paolo Della Bella.
来源: Circ Arrhythm Electrophysiol. 2024年17卷6期e012523页
In the PARTITA trial (Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator?), antitachycardia pacing (ATP) predicted the occurrence of implantable cardioverter defibrillator (ICD) shocks. Catheter ablation of ventricular tachycardia after the first shock reduced the risk of death or worsening heart failure. A threshold of ATPs that might warrant an ablation procedure before ICD shocks is unknown. Our aim was to identify a threshold of ATPs and clinical features that predict the occurrence of shocks and cardiovascular events.
148. Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial.
作者: Duk-Hyun Kang.;Sung-Ji Park.;Sung-Hee Shin.;In-Chang Hwang.;Yeonyee Elizabeth Yoon.;Hyung-Kwan Kim.;Mijin Kim.;Min-Seok Kim.;Sung-Cheol Yun.;Jong-Min Song.;Seok-Min Kang.
来源: Circulation. 2024年149卷24期1865-1874页
The morbidity and mortality rates of patients with heart failure (HF) and functional mitral regurgitation (MR) remain substantial despite guideline-directed medical therapy for HF. We evaluated the efficacy of ertugliflozin for reduction of functional MR associated with HF with mild to moderately reduced ejection fraction.
149. Three-Year Clinical Impact of Murray Law-Based Quantitative Flow Ratio and OCT- or FFR-Guidance in Angiographically Intermediate Coronary Lesions.
作者: Cristina Aurigemma.;Daixin Ding.;Shengxian Tu.;Chunming Li.;Wei Yu.;Yingguang Li.;Antonio Maria Leone.;Enrico Romagnoli.;Rocco Vergallo.;Alessandro Maino.;Carlo Trani.;William Wijns.;Francesco Burzotta.
来源: Circ Cardiovasc Interv. 2024年17卷5期e013191页
The FORZA trial (FFR or OCT Guidance to Revascularize Intermediate Coronary Stenosis Using Angioplasty) prospectively compared the use of fractional flow reserve (FFR) or optical coherence tomography (OCT) for treatment decisions and percutaneous coronary intervention (PCI) optimization in patients with angiographically intermediate coronary lesions. Murray law-based quantitative-flow-ratio (μQFR) is a novel noninvasive method for the computation of FFR. In the present study, we evaluated the clinical impact of μQFR, FFR, or OCT guidance in FORZA trial lesions at 3-year follow-up.
150. Predictors of Success for Pulmonary Vein Isolation With Pulsed-field Ablation Using a Variable-loop Catheter With 3D Mapping Integration: Complete 12-month Outcomes From inspIRE.
作者: Tom De Potter.;Massimo Grimaldi.;Mattias Duytschaever.;Ante Anic.;Johan Vijgen.;Petr Neuzil.;Hugo Van Herendael.;Atul Verma.;Allan Skanes.;Daniel Scherr.;Helmut Pürerfellner.;Gediminas Rackauskas.;Pierre Jais.;Vivek Y Reddy.; .
来源: Circ Arrhythm Electrophysiol. 2024年17卷5期e012667页
We previously presented the safety and early efficacy of the inspIRE study (Study for Treatment of Paroxysmal Atrial Fibrillation [PAF] by Pulsed-field Ablation [PFA] System With Irreversible Electroporation [IRE]). With the study's conclusion, we report the outcomes of the full pivotal study cohort, with an additional analysis of predictors of success.
151. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial.
作者: Nimish N Shah.;Lama Ghazi.;Yu Yamamoto.;Sanchit Kumar.;Melissa Martin.;Michael Simonov.;Ralph J Riello Iii.;Kamil F Faridi.;Tariq Ahmad.;F Perry Wilson.;Nihar R Desai.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷5期e010335页
Lipid-lowering therapy (LLT) is underutilized for very high-risk atherosclerotic cardiovascular disease. PROMPT-LIPID (PRagmatic Trial of Messaging to Providers about Treatment of HyperLIPIDemia) sought to determine whether electronic health record (EHR) alerts improve 90-day LLT intensification in patients with very high-risk atherosclerotic cardiovascular disease.
152. Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial.
作者: Radosław Pracoń.;John A Spertus.;Samuel Broderick.;Sripal Bangalore.;Frank W Rockhold.;Witold Ruzyllo.;Elena Demchenko.;Thuraia Nageh.;Gabriel Blacher Grossman.;Kreton Mavromatis.;Cholenahally N Manjunath.;Paola E P Smanio.;Gregg W Stone.;G B John Mancini.;William E Boden.;Jonathan D Newman.;Harmony R Reynolds.;Judith S Hochman.;David J Maron.; .
来源: Circ Cardiovasc Interv. 2024年17卷6期e013435页
ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) did not find an overall reduction in cardiovascular events with an initial invasive versus conservative management strategy in chronic coronary disease; however, there were conservative strategy participants who underwent invasive coronary angiography early postrandomization (within 6 months). Identifying factors associated with angiography in conservative strategy participants will inform clinical decision-making in patients with chronic coronary disease.
153. Prognostic Impact of Sinus Rhythm in Atrial Fibrillation Patients: Separating Rhythm Outcomes From Randomized Strategy Findings From the CABANA Trial.
作者: T Jared Bunch.;Jeanne E Poole.;Adam P Silverstein.;Kerry L Lee.;Hussein R Al-Khalidi.;Gerhard Hindricks.;Alexander Romanov.;Evgeny Pokushalov.;Tristram D Bahnson.;Melanie R Daniels.;Jonathan P Piccini.;Daniel B Mark.;Douglas L Packer.; .
来源: Circ Arrhythm Electrophysiol. 2024年17卷5期e012697页
Clinically detected atrial fibrillation (AF) is associated with a significant increase in mortality and other adverse cardiovascular events. Since the advent of effective methods for AF rhythm control, investigators have attempted to determine how much these adverse prognostic AF effects could be mitigated by the restoration of sinus rhythm (SR) and whether the method used mattered.
154. Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction: The PiCSO-AMI-I Trial.
作者: Giovanni Luigi De Maria.;John P Greenwood.;Azfar G Zaman.;Didier Carrié.;Pierre Coste.;Marco Valgimigli.;Miles Behan.;Colin Berry.;Andrejs Erglis.;Vasileios F Panoulas.;Eric Van Belle.;Christian Juhl Terkelsen.;Lukas Hunziker Munsch.;Ajay K Jain.;Jens Flensted Lassen.;Nick Palmer.;Gregg W Stone.;Adrian P Banning.
来源: Circ Cardiovasc Interv. 2024年17卷4期e013675页
Primary percutaneous coronary intervention (pPCI) has improved clinical outcomes in patients with ST-segment-elevation myocardial infarction. However, as many as 50% of patients still have suboptimal myocardial reperfusion and experience extensive myocardial necrosis. The PiCSO-AMI-I trial (Pressure-Controlled Intermittent Coronary Sinus Occlusion-Acute Myocardial Infarction-I) evaluated whether PiCSO therapy can further reduce myocardial infarct size (IS) in patients undergoing pPCI.
155. Quality of Life in Patients With Chronic Limb-Threatening Ischemia Treated With Revascularization.
作者: Matthew T Menard.;Alik Farber.;Richard J Powell.;Kenneth Rosenfield.;Michael S Conte.;Taye H Hamza.;John A Kaufman.;Mark J Cziraky.;Mark A Creager.;Michael D Dake.;Michael R Jaff.;Diane Reid.;George Sopko.;Christopher J White.;Michael B Strong.;Max van Over.;Emiliano Chisci.;Philip P Goodney.;Bruce Gray.;Ahmed Kayssi.;Jeffrey J Siracuse.;Niteesh K Choudhry.; .
来源: Circulation. 2024年149卷16期1241-1253页
In the BEST-CLI trial (Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb-Threatening Ischemia), a prespecified secondary objective was to assess the effects of revascularization strategy on health-related quality of life (HRQoL).
156. A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study.
作者: Ivan Netuka.;Zuzana Tucanova.;Peter Ivak.;Stanislav Gregor.;Dushan Michael Kolesar.;Tomas Marek.;Vojtech Melenovsky.;Jana Binova.;Zora Dorazilova.;Marketa Hegarova.;Martina Podolec.;Hynek Riha.;Jean M Connors.;Mandeep R Mehra.
来源: Circulation. 2024年150卷6期509-511页 157. Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial.
作者: David E Kandzari.;Michael A Weber.;Atul Pathak.;James P Zidar.;Manish Saxena.;Shukri W David.;Roland E Schmieder.;Adam J Janas.;Christopher Langer.;Alexandre Persu.;Farrell O Mendelsohn.;Koen Ameloot.;Malcolm Foster.;Tim A Fischell.;Helen Parise.;Felix Mahfoud.
来源: Circulation. 2024年149卷24期1875-1884页
Renal denervation (RDN) has demonstrated clinically relevant reductions in blood pressure (BP) among individuals with uncontrolled hypertension despite lifestyle intervention and medications. The safety and effectiveness of alcohol-mediated RDN have not been formally studied in this indication.
158. Topical Versus Intravenous Tranexamic Acid in Patients Undergoing Cardiac Surgery: The DEPOSITION Randomized Controlled Trial.
作者: André Lamy.;Dmitry A Sirota.;Frederic Jacques.;Ahmad Poostizadeh.;Nicolas Noiseux.;Sergey Efremov.;Philippe Demers.;Boris Akselrod.;Chew Yin Wang.;Rakesh C Arora.;Piotr Branny.;Shay P McGuinness.;Craig D Brown.;Hugues Jeanmart.;Qiang Zhao.;Haibo Zhang.;Emilie P Belley-Côté.;Richard P Whitlock.;Austin Browne.;Ingrid Copland.;Jessica Vincent.;Rutaba Khatun.;Kumar Balasubramanian.;Shrikant I Bangdiwala.;Michael H McGillion.;Alison E Fox-Robichaud.;Jessica Spence.;Salim Yusuf.;P J Devereaux.; .
来源: Circulation. 2024年150卷17期1315-1323页
Although intravenous tranexamic acid is used in cardiac surgery to reduce bleeding and transfusion, topical tranexamic acid results in lower plasma concentrations compared with intravenous tranexamic acid, which may lower the risk of seizures. We aimed to determine whether topical tranexamic acid reduces the risk of in-hospital seizure without increasing the risk of transfusion among cardiac surgery patients.
159. Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial.
作者: Alexander T Sandhu.;Jamie Calma.;Megan Skye.;Neil Kalwani.;Jimmy Zheng.;Jessica Schirmer.;Natasha Din.;Cati Brown Johnson.;Anshal Gupta.;Roy Lan.;Brian Yu.;John A Spertus.;Paul A Heidenreich.
来源: Circulation. 2024年149卷22期1717-1728页
The impact of routine clinic use of patient-reported outcome (PRO) measures on clinical outcomes in patients with heart failure (HF) has not been well-characterized. We tested if clinic-based use of a disease-specific PRO improves patient-reported quality of life at 1 year.
160. Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.
作者: Alexander J Blood.;Lee-Shing Chang.;Shahzad Hassan.;Jacqueline Chasse.;Gretchen Stern.;Daniel Gabovitch.;David Zelle.;Caitlin Colling.;Samuel J Aronson.;Christian Figueroa.;Emma Collins.;Ryan Ruggiero.;Emily Zacherle.;Joshua Noone.;Carey Robar.;Jorge Plutzky.;Thomas A Gaziano.;Christopher P Cannon.;Deborah J Wexler.;Benjamin M Scirica.
来源: Circulation. 2024年149卷23期1802-1811页
Several SGLT2i (sodium-glucose transport protein 2 inhibitors) and GLP1-RA (glucagon-like peptide-1 receptor agonists) reduce cardiovascular events and improve kidney outcomes in patients with type 2 diabetes; however, utilization remains low despite guideline recommendations.
|